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HeBACKGROUND Cisplatin-based chemotherapy increases the risk of cardiovascular and renal disease.
OBJECTIVES We aimed to define the time course, pathophysiology, and approaches to prevent cardiovascular disease
associated with cisplatin-based chemotherapy.
METHODS Two cohorts of patients with a history of testicular cancer (n ¼ 53) were recruited. Cohort 1 consisted of 27
men undergoing treatment with: 1) surveillance; 2) 1 to 2 cycles of bleomycin, etoposide, and cisplatin (BEP) chemo-
therapy (low-intensity cisplatin); or 3) 3 to 4 cycles of BEP (high-intensity cisplatin). Endothelial function (percentage
flow-mediated dilatation) and cardiovascular biomarkers were assessed at 6 visits over 9 months. Cohort 2 consisted of
26 men previously treated 1 to 7 years ago with surveillance or 3 to 4 cycles BEP. Vasomotor and fibrinolytic responses to
bradykinin, acetylcholine, and sodium nitroprusside were evaluated using forearm venous occlusion plethysmography.
RESULTS In cohort 1, the percentage flow-mediated dilatation decreased 24 h after the first cisplatin dose in patients
managed with 3 to 4 cycles BEP (10.9  0.9 vs. 16.7  1.6; p < 0.01) but was unchanged from baseline thereafter. Six
weeks after starting 3 to 4 cycles BEP, there were increased serum cholesterol levels (7.2  0.5 mmol/l vs. 5.5 
0.2 mmol/l; p ¼ 0.01), hemoglobin A1c (41.8  2.0 mmol/l vs. 35.5  1.2 mmol/l; p < 0.001), von Willebrand factor
antigen (62.4  5.4 mmol/l vs. 45.2  2.8 mmol/l; p ¼ 0.048) and cystatin C (0.91  0.07 mmol/l vs. 0.65 
0.09 mmol/l; p < 0.01). In cohort 2, intra-arterial bradykinin, acetylcholine, and sodium nitroprusside caused dose-
dependent vasodilation (p < 0.0001). Vasomotor responses, endogenous fibrinolytic factor release, and cardiovascular
biomarkers were not different in patients managed with 3 to 4 cycles of BEP versus surveillance.
CONCLUSIONS Cisplatin-based chemotherapy induces acute and transient endothelial dysfunction, dyslipidemia, hy-
perglycemia, and nephrotoxicity in the early phases of treatment. Cardiovascular and renal protective strategies should
target the early perichemotherapy period. (Clinical Characterisation of the Vascular Effects of Cis-platinum Based
Chemotherapy in Patients With Testicular Cancer [VECTOR], NCT03557177; Intermediate and Long Term Vascular
Effects of Cisplatin in Patients With Testicular Cancer [INTELLECT], NCT03557164) (J Am Coll Cardiol CardioOnc
2020;2:443–55) © 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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ICAM = intracellular adhesion
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PAI = plasminogen activator
inhibitor
SNP = sodium nitroprusside
t-PA = tissue plasminogen
activator
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444T esticular cancer is the most commonmalignancy in men aged 20 to 40years, and cisplatin-based chemo-
therapy with bleomycin, etoposide, and
cisplatin (BEP) achieves a cure for almost all
patients (1,2). However, this treatment is
associated with cardiovascular disease
(CVD), including myocardial infarction,
thrombosis, and nephrotoxicity (3,4).
Adverse effects on the endothelium appear
to be a central pathophysiological mecha-
nism (5), and perturbations in metabolic
and inflammatory parameters may also be
important (6,7). A retrospective epidemio-
logical study of >15,000 patients demon-
strated a 5-fold increase in standardized
cardiovascular mortality following cisplatin-
based chemotherapy that was confined pri-marily to the first year following treatment (1). This
challenges the preconception that cardiovascular
risk in testicular cancer survivors is a late phenome-
non (3,8).
Historically, the prospective evaluation of vascular
effects of cisplatin-based chemotherapy has been
hindered by assessments in heterogeneous groups
with differing cardiovascular risk, cancer types, and
treatment regimens. Furthermore, examination of
immediate effects has been limited and usually
without longitudinal assessment (9–11). Understand-
ing the time course and pathophysiological basis of
cisplatin-induced vascular and renal injury is critical
to inform surveillance and trials of treatment and
prevention strategies.
Thus, we assessed the effects of cisplatin-based
chemotherapy on endothelial function, metabolic
parameters, fibrinolytic factors, and cardiovascular
and renal biomarkers in the immediate peritreatment
phase followed by prospective, longitudinal assess-
ments over 9 months in men with testicular cancer. In
a further series of studies, we used forearm venous
occlusion plethysmography, the gold standard
method to evaluate endothelial function (12), to
assess endothelial vasomotor and endogenous fibri-
nolytic function in testicular cancer survivors treated
1 to 7 years prior. We also assessed the in vitro effectsns were not involved in the study design or conduct; data collect
pproval of the manuscript. The authors have reported that they h
sclose.
s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
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received January 15, 2020; revised manuscript received June 2,of cisplatin on stress kinase signaling and thrombosis
pathways in human aortic endothelial cell (HAEC)
culture.
METHODS
The studies (NCT03557177 and NCT03557164) were
approved by the West of Scotland Research Ethics
Committee 4 and conducted in accordance with the
Declaration of Helsinki. Written informed consent
was obtained from all participants.
COHORT 1: EARLY EFFECTS OF CISPLATIN-BASED
CHEMOTHERAPY. Study part i c ipants . Patients were
recruited from the Beatson West of Scotland Cancer
Centre between January 2016 and July 2017. Inclusion
criteria included diagnosis of testicular/retroperito-
neal germ cell cancer with orchidectomy #8 weeks
prior and scheduled for cisplatin-based chemotherapy
or surveillance. Participants were categorized into 3
groups: 1) surveillance; 2) 1 to 2 cycles BEP; or 3) 3 to
4 cycles BEP. Exclusion criteria included: carboplatin
treatment; age <18 or >65 years; clinical trial
participation; antiplatelet/lipid-lowering therapy;
recreational drug use; inflammatory/infective/
autoimmune disease; another malignancy in the
previous 5 years; previous thrombosis; and inability
to provide informed consent.
Chemotherapy reg imens . Cisplatin-based chemo-
therapy regimens included BEP or etoposide and
cisplatin (EP). Each treatment cycle lasted 21 days,
with cisplatin administered on days 1 and 2 (cisplatin
dose 50 mg/m2/day) or days 1 to 5 (cisplatin dose
20 mg/m2/day), such that the cumulative dose of
cisplatin in each cycle of treatment was 100 mg/m2.
Patients attended outpatient bleomycin administra-
tion on days 8 and 15 (each dose 30,000 IU). Patients
were treated with etoposide 165 mg/m2 on days 1 to 3
if receiving 1, 3, or 4 cycles of BEP; or etoposide
120 mg/m2 on days 1 to 3 if receiving 2 cycles of BEP.
Patients with stage 1 disease received 1 to 2 cycles of
BEP, a low-intensity cisplatin regimen. Patients with
metastatic disease received 3 or 4 cycles of BEP, a
high-intensity cisplatin regimen. Patients with met-
astatic disease or with a contraindication to bleomy-
cin received 4 cycles of EP, with cisplatinion, analysis and interpretation; nor the preparation,
ave no relationships relevant to the contents of this
es and animal welfare regulations of the authors’
t consent where appropriate. For more information,
2020, accepted June 4, 2020.
FIGURE 1 Cancer Management Regimes and Assessments in Cohort 1 (Early Effects Study)
Patients with a recent diagnosis of testicular/retroperitoneal germ cell cancer and orchidectomy #8 weeks prior scheduled for cisplatin-based
chemotherapy or active surveillance were recruited. Participants were stratified into 3 groups by management: 1) active surveillance for stage
1 low-risk disease; 2) 1 to 2 cycles of adjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy for stage 1 high-risk disease; or 3) 3 to 4
cycles BEP chemotherapy for metastatic disease. Red circles illustrate study assessments.
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445administered over days 1 to 5 (cisplatin dose
20 mg/m2/day) to achieve cumulative cisplatin dose
100 mg/m2. All patients received hydration contain-
ing potassium and magnesium before and after each
cisplatin dose.
Study assessments. Initial assessments were performed
#8 weeks after orchidectomy and #2 weeks pre-
chemotherapy. In patients managed with surveil-
lance, subsequent assessments were 1 to 2 weeks,
6 weeks  3 days, 3 months  1 week, 6 months 
1 week, and 9 months  1 week after the initial
assessment. In patients managed with chemotherapy,
subsequent assessments were within 24 h of cisplatin
administration and 6 weeks  3 days, 3 months 
1 week, 6 months  1 week and 9 months  1 week
(Figure 1). Participants fasted (with the exception of
water) for 8 h and abstained from exercise, caffeine,
and tobacco for 4 h before each assessment. Height,
weight, and blood pressure (BP) were assessed at each
visit.
Pr imary outcome: endothel ia l funct ion . The pri-
mary outcome was change in endothelial function
relative to baseline, assessed using the AngioDe-
fender system (Everist Genomics, Ann Arbor, Michi-
gan). This portable device allows bedside assessment
of endothelial vasomotor function. It calculatespercentage flow-mediated dilatation (%FMD) using a
proprietary algorithm deriving changes in brachial
artery diameter from pulse wave amplitude data
before and after brachial artery occlusion with an
upper arm cuff (13). Maximal post-occlusion change
in brachial artery diameter relative to baseline is
calculated and expressed as %FMD. The repeatability
of AngioDefender %FMD is similar to traditional
brachial artery ultrasound (BAUSS) assessment of %
FMD (coefficient of variation 25.9% and 25.1%,
respectively, according to personal communication
with investigative teams (Everist Health, March 2015)
for NCT02641197 and NCT02682576. AngioDefender
quantification of %FMD is similar to BAUSS (Pearson’s
correlation coefficient, rp ¼ 0.75; p < 0.0001) and
correlates more strongly with 10-year Framingham
risk score (rp ¼ 0.38; p < 0.001 AngioDefender; rp
¼ 0.24; p ¼ 0.03 BAUSS) (14).
Secondary outcomes : card iovascular and renal
b iomarkers . Fasting venous blood was collected at
each visit. Serum creatinine, lipid profile, glycated
hemoglobin A1c (HbA1C), and urine albumin to
creatinine ratio (ACR) were measured in the local
clinical laboratory. Estimated glomerular filtration
rate (eGFR) was calculated using the 2009
Chronic Kidney Disease Epidemiology Collaboration












Age, yrs 39  3 31  2 34  2
Height, m 1.79  0.02 1.78  0.03 1.77  0.03
Weight, kg 93.5  7.0 90.4  5.8 88.7  3.8
Body mass index, kg/m2 28.9  2.0 28.3  1.4 28.3  1.1
Systolic blood pressure, mm Hg 122.9  5.3 134.1  3.4 131.7  4.3
Diastolic blood pressure, mm Hg 73.1  4.2 76.7  2.9 79.0  3.0
Heart rate, beats/min 66.7  3.0 70.9  5.3 64.7  2.8
Cholesterol, mmol/l 5.2  0.3 5.1  0.5 5.5  0.2
Triglycerides, mmol/l 1.2  0.2 1.1  0.2 1.9  0.5
LDL cholesterol, mmol/l 3.3  0.3 3.4  0.4 3.5  0.2
HDL cholesterol, mmol/l 1.2  0.1 1.3  0.1 1.8  0.4
Glucose, mmol/l 4.9  0.1 5.1  0.2 5.0  0.2
HbA1c, mmol/mol 34.7  1.1 33.1  1.0 35.5  1.2
vWF:Ag, % 44.3  4.8 38.4  3.4 45.2  2.8
Log urine ACR, mg/l 0.18  0.10 0.23  0.08 0.14  0.05
Histological diagnosis
Seminoma 7 (70) — 2 (20)
Nonseminoma/mixed 3 (30) 7 (100) 8 (80)
Performance status
0 10 (100) 7 (100) 6 (60)
1 — — 4 (40)
Medical history
Hypertension 1 (10) — 1 (10)
Diabetes - — —
Smoker 1 (10) — —
Medications
Alpha-blocker — — 1 (10)
Angiotensin-II receptor blocker — — 1 (10)
Values aremean SEMorn (%). Units reported inmmol/l canbe converted tomg/dl through the followingconversion
factors: cholesterol mmol/l ¼ mg/dlO 38.6; triglyceride mmol/l¼ mg/dlO 88.5; Glucose mmol/l ¼ mg/dlO 18.
ACR ¼ albumin to creatinine ratio; BEP ¼ bleomycin, etoposide, and cisplatin; HDL ¼ high-density lipoprotein;
LDL ¼ low-density lipoprotein; vWF:Ag ¼ von Willebrand factor antigen.
Cameron et al. J A C C : C A R D I O O N C O L O G Y , V O L . 2 , N O . 3 , 2 0 2 0
Vascular Effects of Cisplatin-Based Chemotherapy S E P T E M B E R 2 0 2 0 : 4 4 3 – 5 5
446creatinine equation (15). Enzyme-linked immunosor-
bent assays were performed to measure serum tissue
plasminogen activator (Asserachrom, Stago, Reading,
United Kingdom), plasminogen activator inhibitor-1
(Asserachrom), von Willebrand factor (vWF) (Asser-
achrom), and intracellular adhesion molecule
(ICAM)-1 (Quantikine, R&D Systems, Abingdon,
United Kingdom). Cystatin-C was measured using a
particle enhanced turbidimetric immunoassay (Tina-
quant, Roche, Germany). Serum high-sensitivity C-
reactive protein and lipoprotein(a) were measured
(Roche c311 analyzer) and high-sensitivity troponin-I
was measured (Abbot, Architect i1000SR). Urine was
collected for assessment of interleukin (IL)-18
(Quantikine, R&D Systems).
COHORT 2: MEDIUM-TERM EFFECTS OF CISPLATIN-BASED
CHEMOTHERAPY. Part i c ipants . Testicular cancer sur-
vivors age 18 to 50 years managed with 3 to 4 cycles ofBEP or active surveillance 1 to 7 years previously were
recruited. Exclusion criteria included ongoing clinical
trial participation; vascular disease; asthma; chronic
obstructive pulmonary disease; diabetes; atrial
fibrillation/flutter; anticoagulation; tobacco/recrea-
tional drug use; inflammatory, infectious, or auto-
immune disease; another malignancy within 7 years;
and prior thrombosis.
Forearm venous occ lus ion plethysmography .
Studies were performed with the patient supine in a
quiet, temperature-controlled room. Participants
fasted for 4 h, abstained from alcohol for 24 h, and did
not consume medications for 3 days before each
study. Bilateral venous cannulae were inserted into
large antecubital fossa veins for venous sampling.
Brachial artery cannulation was performed using a
27-standard-wire-gauge steel needle for intra-arterial
administration of locally active doses of drugs. Fore-
arm blood flow (FBF) was measured in the infused
and noninfused arms by venous occlusion plethys-
mography. Supine heart rate (HR) and BP were
monitored (12,16).
Pharmaceut ica l agents . Pharmaceutical-grade bra-
dykinin (BK) (Bachem, Bubendorf, Switzerland),
acetylcholine (ACh) (Novartis Pharmaceuticals, Lon-
don, United Kingdom), and sodium nitroprusside
(SNP) (UL Medicines, Surrey, United Kingdom) were
dissolved in physiological saline. BK is an
endothelium-dependent vasodilator that provokes
endothelial release of tissue plasminogen activator
(t-PA). ACh is an endothelium-dependent vasodilator
that does not provoke t-PA release. SNP is an
endothelium-independent vasodilator.
Outcomes . The primary outcome was change in
BK-induced vasodilation. Secondary outcomes were
change in ACh- and SNP-induced vasodilation,
BK-induced tPA and plasminogen activator inhibitor
(PAI)-1 release, and between-group differences in
cardiovascular biomarkers.
In tra-ar ter ia l drug admin is t rat ion . After a 20-min
intra-arterial 0.9% saline infusion, participants
received ascending doses of BK (100, 300, and 1,000
pmol/min), ACh (5, 10, and 20 mg/min), and SNP (2, 4,
and 8 mg/min) for 6 min at each dose, with a 20-min
0.9% saline washout between agents. The infusion
rate was maintained at 1 ml/min and the infusion
order was randomized for each volunteer.
Blood sampl ing . Venous blood was collected at
baseline for lipid profile, HbA1C, vWF antigen, and
ICAM-1 concentration (Vacuette, Kremsmünster,
Austria). Full blood count, renal function, liver
function, lipid profile, glucose, and HbA1C concen-
trations were measured in local clinical laboratories.
Blood samples were simultaneously drawn from each
FIGURE 2 Cohort 1 (Early Effects Study): %FMD Score
Changes in %FMD among patients managed with surveillance (dark blue line), 1 to 2
cycles bleomycin, etoposide, and cisplatin (BEP) (light blue line), and 3 to 4 cycles BEP
(red line). The blue and red shaded rectangles refer to duration of chemotherapy
treatment (solid blue ¼ 1 cycle, light blue ¼ 2 cycles; solid red ¼ 3 cycles, light red ¼ 4
cycles). Shaded areas indicate chemotherapy. **p < 0.01. BL ¼ baseline; FMD ¼ flow-
mediated dilatation; m ¼ month; W ¼ week.
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447arm at the end of equilibration and each BK dose into
acidified buffered citrate (TriniLIZE Stabilyte, Co.,
Wicklow, Ireland) for t-PA assays and citrate (Vacu-
ette) for analysis of PAI-1 (the major endogenous in-
hibitor of t-PA). Enzyme-linked immunosorbent
assays were performed as described in the previous
text to determine concentrations of t-PA antigen,
PAI-1 antigen, vWF and ICAM-1, and PAI-1 activity (2B
Scientific, Oxfordshire, United Kingdom).
HUMAN AORTIC ENDOTHELIAL CELLS. HAECs (Life
Technologies, Paisley, United Kingdom) were
cultured in endothelial cell growth medium (Promo-
cell, Heidelberg, Germany) supplemented with 15 ml
SupplementMix (Promocell) and penicillin/strepto-
mycin 50 mg/ml. Confluent cells were rendered
quiescent by serum starvation for 2 h in low-serum
medium with 0.5% fetal bovine serum. Cells were
stimulated with cisplatin (1, 3, or 15 mg/ml) (Accord
Healthcare, Devon, United Kingdom) or vehicle
(phosphate-buffered saline) for 5 min, 15 min, and
24 h.
Immunoblott ing . HAECs were homogenized in lysis
buffer and proteins (30 mg) were separated by elec-
trophoresis as described previously (17). Membranes
were probed with antiphosphorylated Akt (Cell Sig-
nalling [Danvers, Massachusetts] 4060, 1:1,000) and
antiphosphorylated extracellular signal-regulated
kinases 1/2 (ERK 1/2) (Cell Signalling 9101, 1:1,000).
Protein phosphorylation levels were normalized to
a-tubulin (Abcam ab4074, 1:1,0000) and expressed as
percentage of the respective time point control,
which was taken as 100%.
Quantitative real-time polymerase chain reaction.mRNA
expression of t-PA (QT00075761, Qiagen, Manchester,
United Kingdom) and PAI-1 (QT00062496, Qiagen)
was assessed by qPCR. Total RNA was extracted using
TRIzol (Qiagen) as previously described (17). Data are
expressed as target gene/GAPDH housekeeping gene
(Sense: GAGTCAACGGATTTGGTCGT; Anti-Sense:
TTGATTTTGGAGGGATCTCG; Eurofins Genomics,
Ebersberg, Germany). Relative gene expression was
calculated by the 2-DDCt method, and results were
compared with control.
DATA ANALYSIS AND STATISTICS. Cohort 1 : ear ly
effects of c i sp la t in-based chemotherapy . Data
were analyzed using 2-way analysis of variance
(ANOVA) with repeated measures based on the gen-
eral linear model and Dunnett’s correction for multi-
ple comparisons. Power calculations determined that,
at a significance of 5%, 10 subjects/group would pro-
vide 90% power of detecting 1.6% difference in %
FMD between visits by paired Student’s t-test with SDof paired difference of 1.4 (13). Serum lipoprotein(a),
urine ACR, and urine IL-18 (adjusted for urine creat-
inine concentration) were logarithmically trans-
formed to ensure normality.
Cohort 2: medium-term effects of cisplatin-based
chemotherapy. Forearm plethysmographic data
were analyzed as described previously (18). Net t-PA
and PAI-1 release were defined as the product of the
infused forearm plasma flow and the concentration
difference between infused and noninfused arms
(18). Previous studies demonstrated that 8 subjects
per group provides sufficient power to detect an
approximately 20% change in FBF at 5% significance
(19,20). The influence of a range of factors on FBF
responses have been reported in similar sample sizes
(21–24). Analysis was by repeated measures based on
the general linear model or 1-way ANOVA.
ENDOTHELIAL CELL CULTURE. Data were analyzed
by 1-way ANOVA with Dunnett’s correction for mul-
tiple comparisons (Western Blot analyses) or un-
paired Student’s t-test (mRNA expression). Relative
mRNA expression values were logarithmically trans-
formed to ensure normality.
Variables are reported as mean  SEM. Statistical
analyses were performed using GraphPad Prism
(GraphPad Software, La Jolla, California) with statis-
tical significance at 5%.
TABLE 2 Cohort 1 (Early Effect): Cardiovascular Biomarkers
Chol (mmol/l) HDL-C (mmol/l) LDL-C (mmol/l) TGs (mmol/l) Gluc (mmol/l) HbA1C (mmol/mol) vWF:Ag (%)
Surveillance (n ¼ 10)
BL 5.2  0.3 1.2  0.1 3.3  0.3 1.2  0.2 4.9  0.1 34.7  1.1 44.3  4.8
1–2 weeks 5.1  0.3 1.3  0.1 3.2  0.2 1.1  0.2 4.9  0.1 34.2  0.9 42.8  5.2
6 weeks 5.0  0.3 1.2  0.1 3.2  0.2 1.2  0.1 5.0  0.2 33.4  0.8 45.9  5.3
3 months 4.7  0.3 1.2  0.1 3.0  0.2 1.1  0.1 5.1  0.2 33.8  0.7 43.2  4.1
6 months 4.7  0.3 1.2  0.1 2.9  0.2 1.2  0.2 5.1  0.2 33.8  0.5 48.2  4.6
9 months 4.8  0.4 1.2  0.1 3.0  0.2 1.2  0.2 5.0  0.2 35.0  1.0 51.2  6.7
1–2 cycles of BEP (low-intensity cisplatin) (n ¼ 7)
BL 5.1  0.5 1.3  0.1 3.4  0.4 1.1  0.2 5.1  0.2 33.1  1.0 38.4  3.4
24 h 4.9  0.4 1.3  0.1 3.3  0.4 0.7  0.1 6.9  0.2* 33.7  0.9 43.1  1.6
6 weeks 5.8  0.8 1.2  0.1 3.8  0.7 2.1  0.3 5.1  0.2 35.6  1.1 52.8  1.9
3 months 5.1  0.8 1.2  0.1 3.4  0.7 1.5  0.3 5.0  0.2 30.0  0.7 44.3  6.0
6 months 5.2  0.5 1.2  0.1 3.4  0.4 1.4  0.3 4.9  0.1 35.0  1.1 55.8  8.4
9 months 4.9  0.4 1.2  0.1 3.2  0.3 1.2  0.1 5.2  0.2 32.7  0.9 55.0  8.2
3–4 cycles of BEP (high-intensity cisplatin) (n ¼ 10)
BL 5.5  0.2 1.8  0.4 3.5  0.2 1.9  0.5 5.0  0.2 35.5  1.2 45.2  2.8
24 h 5.7  0.3 1.8  0.4 4.0  0.3 1.1  0.2 6.6  0.2* 35.3  1.3 42.4  2.7
6 weeks 7.2  0.5† 2.3  0.6 4.7  0.5 2.6  0.5 5.2  0.3 41.8  2.0* 62.4  5.4†
3 months 6.7  0.4 1.8  0.4 4.2  0.4 3.1  0.7 5.0  0.1 29.1  1.7* 48.9  3.8
6 months 6.2  0.4 1.7  0.4 3.8  0.3 2.9  0.5 5.1  0.2 37.8  0.9 47.7  4.9
9 months 6.1  0.3 1.8  0.5 4.1  0.3 2.4  0.3 5.1  0.2 33.8  0.9 48.2  3.0
Values are mean  SEM. *p < 0.001; †p < 0.05.
BL ¼ baseline; Chol ¼ cholesterol; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; gluc ¼ glucose; hs-CRP ¼ high-sensitivity C-reactive protein; hs-TNI ¼ high-
sensitivity troponin I; ICAM ¼ intracellular adhesion molecule; PAI ¼ plasminogen activator inhibitor; TG ¼ triglyceride; t-PA ¼ tissue plasminogen activator; vWF:Ag ¼ von Willebrand factor antigen.
Continued on the next page
TABLE 3 Cohort 2 (Medium-Term Effects): Baseline




3 to 4 Cycles of BEP
(n ¼ 12)
Age, yrs 38  2 36  2
Body mass index, kg/m2 25.6  0.9 26.9  0.8
Systolic blood pressure, mm Hg 122.6  3.7 128.4  3.1
Diastolic blood pressure, mm Hg 74.9  2.7 74.1  2.7
Heart rate, beats/min 60.1  2.5 60.9  3.3
Cholesterol, mmol/l 5.1  0.3 4.9  0.3
Triglycerides, mmol/l 1.2  0.2 1.4  0.2
LDL cholesterol, mmol/l 3.2  0.3 3.1  0.2
HDL cholesterol, mmol/l 1.4  0.1 1.3  0.1
Glucose, mmol/l 4.7  0.1 4.5  0.4
HbA1c, mmol/mol 32.7  0.7 33.1  0.8
vWF:Ag, % 40.1  2.2 43.0  1.1
Histological diagnosis
Seminoma 8 (57) 2 (17)
Nonseminoma/mixed 6 (43) 10 (83)
Performance status
0 14 (100) 12 (100)
Values are mean  SEM or n (%). Units reported in mmol/l can be converted to
mg/dl through the following conversion factors: cholesterol mmol/l ¼ mg/dl O
38.6; triglyceride mmol/l ¼ mg/dl O 88.5; glucose mmol/l ¼ mg/dl O 18.
Abbreviations as in Table 2.
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COHORT 1: EARLY EFFECTS OF CISPLATIN-BASED
CHEMOTHERAPY. Vascular funct ion . Participant
characteristics are presented in Table 1. %FMD
decreased 24 h after the first dose of cisplatin in the
10 patients managed with 3 to 4 cycles of BEP (16.7 
1.6 at baseline vs. 10.9  0.9 at 24 h after cisplatin;
p ¼ 0.003) (Figure 2). At 6 weeks, %FMD had returned
to baseline (15.7  2.1; p ¼ 0.97 vs. baseline) (Figure 2,
Supplemental Table 1). %FMD was unchanged
compared with baseline at all other times (Figure 2)
(all p > 0.05). In the 7 patients managed with 1 to 2
cycles of BEP or surveillance, %FMD was not signifi-
cantly different from baseline at any point (Figure 2)
(p > 0.05). %FMD data were available for 157 of 162
study visits. Resting BP and HR were unchanged
during treatment and follow-up in all groups (p ¼ NS
for all; data not shown).
Card iovascu lar b iomarkers . In patients managed
with 3 to 4 cycles of BEP, serum cholesterol increased
at 6 weeks (7.2  0.5 mmol/l vs. 5.5  0.2 mmol/l at
baseline; p ¼ 0.012) (Table 2). This remained numer-
ically greater than baseline thereafter, but was not
statistically significant. There were trends toward
TABLE 2 Continued
t-PA (ng/ml) PAI-1 (ng/ml) hs-CRP (mg/l) ICAM-1 (ng/ml) hs-TNI (pg/ml) Log Urine ACR (mg/l)
11.9  2.5 111.2  4.3 2.1  1.0 408.1  37.4 0.24  0.16 0.18  0.10
13.5  3.1 116.7  3.3 2.1  0.7 389.3  47.7 0.19  0.19 0.30  0.05
12.1  2.4 113.0  3.1 1.7  0.7 387.6  39.1 0.47  0.35 0.25  0.06
12.8  2.5 111.3  5.3 2.0  0.8 417.4  32.1 0.13  0.13 0.30  0.04
13.7  2.6 110.9  3.9 3.4  1.8 454.9  58.9 0.15  0.11 0.18  0.07
16.7  2.4 101.8  6.2 1.8  0.8 460.4  23.4 0.31  0.21 0.22  0.07
9.0  1.2 105.6  8.0 3.8  1.5 353.6  37.5 0.19  0.19 0.23  0.08
6.1  0.9 108.9  6.7 2.2  0.5 355.1  32.6 0.43  0.29 0.13  0.04†
7.2  0.9 109.5  2.8 4.4  1.9 437.8  57.7 1.21  0.50 0.21  0.05
10.5  2.4 111.1  3.7 3.4  1.3 436.9  49.7 0.24  0.24 0.21  0.15
15.4  3.6 105.0  5.9 1.6  0.5 452.7  41.3 0.94  0.51 0.29  0.10
13.4  3.2 101.7  8.0 4.0  2.1 425.6  45.0 0.27  0.27 0.09  0.18
13.4  1.3 114.4  2.8 2.7  1.5 411.1  28.9 0.83  0.55 0.14 0.05†
13.5  1.3 110.7  2.9 1.4  0.5 382.2  32.1 0.12  0.12 0.20  0.07†
14.6  2.7 115.5  3.7 3.1  1.6 460.8  43.1 1.39  0.63 0.20  0.16
15.1  2.0 104.5  3.5 3.7  1.9 495.2  20.5 1.41  0.70 0.23  0.08
16.1  2.6 108.0  3.2 1.5  0.4 392.2  62.4 0.47  0.24 0.28  0.07
15.3  2.5 110.4  3.9 3.4  1.5 440.8  40.1 1.22  0.40 0.17  0.08
FIGURE 3 Cohort 1 (Early Effects Study): Renal Biomarkers
Changes in renal biomarkers among patients managed with surveillance (purple line), 1 to 2 cycles BEP (blue line), and 3 to 4 cycles BEP (red line): (A) Log urine ACR;
(B) eGFR; (C) serum cystatin C; (D) log urine IL-18 per urine creatinine. Shaded areas indicate chemotherapy. The p values represent 2-way analysis of variance with
correction for multiple comparisons. *p < 0.05; **p < 0.01; ***p < 0.001. ACR ¼ albumin to creatinine ratio; Cr ¼ creatinine; eGFR ¼ estimated glomerular filtration
rate; IL ¼ interleukin; other abbreviations as in Figure 2.
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450increased triglycerides and low-density lipoprotein
(LDL) cholesterol in patients managed with 3 to 4
cycles of BEP (p ¼ 0.076 and p ¼ 0.079 vs. baseline).
This pattern was not seen in the other groups. Serum
fasting glucose increased within 24 h in patients
managed with 1 to 2 or 3 to 4 cycles of BEP (both p <
0.0001 vs. baseline), but did not change in patients
managed with surveillance. There was a rise in HbA1c
in the patients receiving 3 to 4 cycles of BEP at
6 weeks (p < 0.001), but thereafter it was not elevated
versus baseline. vWF antigen increased at 6 weeks
versus baseline in the 3 to 4 cycles of BEP group
(p ¼ 0.048) but was not different from baseline at any
other time point or in any other group. High sensi-
tivity troponin-I, ICAM-1, and high-sensitivity C-
reactive protein were unchanged throughout
(Table 2).
Rena l b iomarkers . In patients managed with 3 to 4
cycles of BEP, urine ACR increased at 24 h and
6 weeks (p ¼ 0.011 and p ¼ 0.014) and returned to
baseline thereafter (Figure 3). Urine IL-18 increased at
24 h (p ¼ 0.023) and returned to baseline by 6 weeks.
Serum cystatin C increased at 24 h (p ¼ 0.012) and
6 weeks (p ¼ 0.004) and returned to baseline there-
after. eGFR was unchanged throughout (Figure 3).
Urine ACR and IL-18 increased 24 h after 1 to 2 cycles
of BEP (p ¼ 0.038 and p ¼ 0.039) and returned to
baseline by 6 weeks. There were no other significant
changes in this group or patients managed with
surveillance.
COHORT 2: MEDIUM-TERM EFFECTS OF CISPLATIN-BASED
CHEMOTHERAPY. Forearm arter ia l vasomotor
funct ion . Baseline characteristics are presented in
Table 3. Intra-arterial BK, ACh, and SNP evoked
dose-dependent vasodilation in all participants (all
p < 0.0001) (Figure 4). Vasodilator responses to BK,
ACh, and SNP were not different in patients managed
with 3 to 4 cycles of BEP (n ¼ 12) versus surveillance
(n ¼ 14) (p ¼ 0.811, 0.866, and 0.938, respectively
(Figure 4, Supplemental Table 2). BK-induced vaso-
dilation data were available in 11 of 12 subjects
managed with 3 to 4 cycles of BEP and all 14 subjects
(100%) managed with surveillance.
BK- induced release of fibr inolyt i c factors . BK
evoked dose-dependent net t-PA antigen release in
patients managed with surveillance (1.8  10.6 ng/
100 ml/min [baseline] vs. 316.4  57.3 ng/100 ml/min
[BK 1,000 ng/min]; p < 0.001) and 3 to 4 cycles of BEP
(7.7  7.7 ng/100 ml/min [baseline] vs. 263.9 
67.7 ng/100 ml/min [BK 1,000 ng/min]; p < 0.001).
There was no differences between groups (p ¼ 0.285).
BK did not evoke changes in net PAI-1 antigen in
patients managed with surveillance (p ¼ 0.524) or 3 to4 cycles BEP (p ¼ 0.502) and responses were not
different between groups (p ¼ 0.946).
IN VITRO EFFECTS OF CISPLATIN ON THROMBOTIC
AND STRESS KINASE PATHWAYS. HAEC exposure to
cisplatin 3 mg/ml for 15 min increased Akt phosphor-
ylation compared with control (n ¼ 5; p ¼ 0.032)
(Figure 5). No changes were observed with other
concentrations or periods of cisplatin exposure.
Similar results were found for ERK 1/2 phosphoryla-
tion (n ¼ 5; p ¼ 0.026). t-PA mRNA expression
decreased in cells exposed to cisplatin (n ¼ 7;
p ¼ 0.014), whereas PAI-1 mRNA expression was un-
changed (n ¼ 7; p ¼ 0.122) (Figure 5).
DISCUSSION
Cisplatin-based chemotherapy is associated with
endothelial vasomotor dysfunction, hypercholester-
olemia, hyperglycemia, and renal dysfunction in
testicular cancer patients (Central Illustration). These
effects are confined to the immediate peri-
chemotherapy period. Our observations suggest the
early time period post-cisplatin treatment is one that
is potentially of increased renal and cardiovascular
risk, and one during which attention should be given
to risk reduction with cardiovascular protection
strategies.
A strength of the study is the early assessment of
endothelial vasomotor function within 24 h following
chemotherapy. Prior studies evaluating vascular
function after cisplatin-based chemotherapy are
limited by infrequent assessments performed months
or years following treatment (6,9), potentially
missing the period of maximum vascular injury and
dysfunction. We demonstrate that, following 3 to 4
cycles of BEP, endothelial function is impaired at this
acute and vulnerable time. Although endothelial
function returned to baseline values at the subse-
quent 6-week assessment, it is biologically plausible
that a similar transient deterioration in endothelial
function is induced with each treatment cycle (5).
Endothelial dysfunction is a key feature in de novo
thrombosis and rupture of pre-existing atheroscle-
rotic plaque (25). As such, it is an important compo-
nent to the risk of thrombotic cardiovascular events
in the early period following cisplatin-based
chemotherapy.
In our cell-based study, exposure of HAECs to
cisplatin was associated with decreased t-PA mRNA
expression and activation of Akt and ERK 1/2. In
previous work, cisplatin has been shown to reduce
endothelial cell survival and induce apoptosis in hu-
man dermal microvascular endothelial cells (HMEC-1)
FIGURE 4 Cohort 2 (Medium-Term Effects Study): Absolute Forearm Blood Flow
Changes in absolute forearm blood flow among patients managed 1 to 7 years previously
with orchidectomy plus 3 to 4 cycles BEP (red line) versus orchidectomy alone (blue line):
(A) bradykinin 100, 300, and 1,000 pmol/min; (B) acetylcholine 5, 10, and 20 mg/min;
(C) sodium nitroprusside 2, 4, and 8 mg/min. The p values represent 2-way analysis of
variancewith correction formultiple comparisons. ACh¼ acetylcholine; BK¼ bradykinin;
SNP ¼ sodium nitroprusside; other abbreviations as in Figure 2.
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451(26) and in the vasa nervorum in rats (27). These data
support the hypothesis that cisplatin induces direct
endothelial toxic effects resulting in increased stress
kinase signaling and a propensity for thrombosis via
reduction in the capacity for endogenous fibrinolysis.
Although adverse thrombotic effects are most
frequently observed in the early period following
chemotherapy, cisplatin is detectable in serum for
several years after treatment (28). This chronic
exposure may provoke low-grade endothelial stimu-
lation and a consequent pro-atherogenic environ-
ment (28,29). Our subsequent assessment was with
forearm venous occlusion plethysmography, the gold
standard for assessing endothelial function (12). In
patients treated 1 to 7 years previously, there was no
difference in endothelial vasomotor function be-
tween patients managed with orchidectomy and
cisplatin-based chemotherapy versus those managed
with orchidectomy alone. Furthermore, BK-induced
t-PA release was not different in patients managed
with or without cisplatin-based chemotherapy. The
capacity for endothelial t-PA release is a sensitive,
and mechanistically relevant, marker for the predic-
tion of patients at risk of cardiovascular events (30).
Serum cholesterol and HbA1C increased transiently
at 6 weeks after 3 to 4 cycles of BEP and similar trends
were seen for LDL cholesterol and triglycerides.
Although cisplatin-based chemotherapy may have
contributed to these observations, we cannot
conclude that this is the only explanation. Indeed, a
reduction in tumor burden may have contributed to
increases in cholesterol (31). Furthermore, glucocor-
ticoid antiemetics may have contributed to changes
in lipid profile and glycemia. However, we do not
believe glucocorticoids are the sole explanation for
the change in lipid parameters. Indeed, in a ran-
domized study in which dexamethasone or placebo
were given to healthy male volunteers, dexametha-
sone did not affect endothelial function, tri-
glycerides, or LDL cholesterol, albeit with a different
dexamethasone regimen to our study (32).
Most studies evaluating the risk of CVD after
cisplatin-based chemotherapy have focused on the
later period after treatment (3,8,33,34). In the 10 to 19
years following treatment, a 5- to 7-fold increased risk
of CVD has been reported compared with patients
managed with surveillance or the general population
(8,33). Larger studies of up to 2,700 patients demon-
strate a more modest 1.5- to 2-fold increased risk of
CVD at 10 to 18 years after treatment (3,34). However,
the incidence of thrombosis appears to be highest
early after treatment. Between 9% and 11% have a
thrombotic event within 1 year following 3 or more
cycles of cisplatin-based chemotherapy (9,35).Importantly, a more granular assessment of 15,006
patients revealed a 5-fold increased risk of cardio-
vascular death in the first year after treatment. This
risk fell dramatically thereafter and was not signifi-
cant after 1 year (1). Therefore, in keeping with our
observations, the early period after treatment with 3
or more cycles of cisplatin-based chemotherapy
FIGURE 5 In Vitro Effects From Cisplatin on Stress Kinase Signaling and Thrombotic Pathways in Human Aortic Endothelial Cells
Effects from cisplatin on phosphorylation of Akt (A) and ERK1/2 (B), and mRNA expression of t-PA (C) and PAI-1 (D). The p values represent 1-way analysis of variance
with correction for multiple comparisons (Western Blot analyses) or unpaired Student’s t-test (mRNA expression). *p < 0.05. 5ʹ ¼ 5 min; 15ʹ ¼ 15 min; (1) ¼ cisplatin
1 mg/ml; (3) ¼ cisplatin 3 mg/ml; (15) ¼ cisplatin 15 mg/ml; Cis ¼ cisplatin; CTR ¼ control; PAI ¼ plasminogen activator inhibitor; t-PA ¼ tissue plasminogen activator.
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vascular risk. While these effects predominantly
occur in the early period after treatment, cisplatin is
detectable in serum several years after treatment
(28). It remains possible that chronic exposure to low
levels of cisplatin may cause low-grade endothelial
stimulation that contributes to the pathophysiology
underlying cardiovascular events occurring more
than a decade after initial exposure (8,28).
Nephrotoxicity is a major, dose-limiting side effect
of cisplatin that affects 20% to 40% of patients (4,36).
We found evidence of early nephrotoxicity following
3 to 4 cycles of BEP as illustrated by increased serum
cystatin C (37). Importantly, this returned to baseline
by 3 months and, although there was an absolute
decrease in eGFR, the change in this less-sensitive
measure did not reach statistical significance.
Increased urinary ACR in the immediate period
following chemotherapy supports the hypothesis that
cisplatin induces renovascular endothelial andproximal tubular dysfunction and inflammation as
evidenced by the rise in urinary IL-18 (4,36,38). We
hypothesize that this profile of renal injury is
compatible with widespread endothelial activation
and injury.
STUDY LIMITATIONS. To our knowledge this is one
of the most comprehensive, longitudinal evalua-
tions of changes in vascular and renal function after
cisplatin-based chemotherapy. However, there are
some limitations that should be acknowledged. The
number of patients in cohort 1 is small, particularly
the group managed with 1 to 2 cycles of BEP, and it
is not possible to conclude whether associations in
this group did not reach statistical significance
because of reduced power or because greater cancer
burden potentiates the toxic effect of cisplatin-
based chemotherapy. Furthermore, we did not
adjust for potential confounders that may have
contributed, such as the baseline elevated BMI in all
CENTRAL ILLUSTRATION Effects of Cisplatin-Based Chemotherapy on Endothelial Function
Cameron, A.C. et al. J Am Coll Cardiol CardioOnc. 2020;2(3):443–55.
Patients with testicular cancer managed with cisplatin-based chemotherapy or surveillance were enrolled. Endothelial function was assessed by % flow-mediated
dilatation over 9 months in patients with a recent diagnosis, or venous occlusion plethysmography in patients managed 1 to 7 years previously. Acute and transient
endothelial dysfunction was observed 24 h after cisplatin-based chemotherapy, and endothelial function was not impaired 1 to 7 years after treatment. In the left
panel, the blue and red shaded rectangles refer to duration of chemotherapy treatment (solid blue ¼ 1 cycle, light blue ¼ 2 cycles; solid red ¼ 3 cycles, light red
4 ¼ cycles). Shaded areas indicate chemotherapy. **p < 0.01.
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453groups, acute hyperglycemia perhaps due to ste-
roids, and an acute inflammatory response to tumor
cell death.
Vascular function was assessed using different
approaches in the acute and long-term studies. The
use of portable equipment allowed assessment of
endothelial function at the patient’s bedside in the
immediate post-chemotherapy period. We reserved
the use of forearm venous occlusion plethysmog-
raphy for studies in survivors after 1 year. These
techniques primarily examine function at different
levels of the arterial tree, and we accept this as a
limitation. We did not use forearm venousocclusion plethysmography to assess the early
vascular effects of cisplatin because this requires
arterial cannulation in the context of a potentially
pro-thrombotic state and is impractical in the peri-
chemotherapy period. Serial assessment of %FMD
each day during chemotherapy provides insight to
the duration of effects from cisplatin on endothelial
function; it would be helpful to assess %FMD in the
period at least 1 year after treatment, but we
limited assessments to maximize recruitment and
retention of patients undergoing intensive treat-
ment regimes. Although AngioDefender %FMD
correlates with Framingham risk score (14), it has
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Cisplatin-based chemotherapy is associated with
acute and transient endothelial dysfunction, dyslipi-
demia, hyperglycemia, and nephrotoxicity in patients
with testicular cancer. Our findings suggest that the
early period following cisplatin-based chemotherapy
is an important time period where functional and
biological perturbations in cardiovascular and renal
function occur.
TRANSLATIONAL OUTLOOK: The early period
following cisplatin-based chemotherapy may be an
important window for surveillance and aggressive
management of cardiovascular and renal health. Early
preventive strategies, including those with statins and
antithrombotic therapies, should be further investi-
gated in patients treated with cisplatin-based
chemotherapy to mitigate cardiovascular risk in the
long-term.
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454not been demonstrated that AngioDefender %FMD
is independently predictive of cardiovascular risk.
Although we demonstrate deleterious effects of
cisplatin-based chemotherapy in the early phase
that are not evident in the medium-term, these
findings could be further strengthened by the in-
clusion of a larger number of participants and
the assessment of survivors treated >7 years pre-
viously. Heightened risk of CVD is reported up to
20 years after cisplatin-based chemotherapy (8),
although endothelial function has not been
assessed beyond 7 years after treatment, and it
remains possible that endothelial dysfunction is
also detectable in longer-term survivors.
CONCLUSIONS
Acute and transient endothelial toxicity, dyslipide-
mia, hyperglycemia, and nephrotoxicity are apparent
in the early period following cisplatin-based chemo-
therapy, when cardiovascular risk is greatest (1). Our
data highlight the early perichemotherapy period as
an important window for focused surveillance of
cardiovascular and renal health during which base-
line and emergent cardiovascular risk factors
should be treated aggressively. The evaluation of
short-term preventative strategies, such as statins
and antithrombotic therapies, is warranted in this
group to allow cancer survivorship to come at the
minimum cardiovascular cost.
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